Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin with sodium restriction versus usual sodium intake in type 2 diabetes and chronic kidney disease
ACTRN12621000152820Phase 4Withdrawn
- Sponsor
- St Vincent's Hospital
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) (2 arms), sponsored by St Vincent's Hospital. Primary endpoint: Change in 24-hour ambulatory blood pressure. Planned start Feb 2021; status: withdrawn.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ACTRN12621000152820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000152820.